gastroenterology
Medicines

Coeliac “vaccine” to enter Phase 2 trials

Phase 2 trials about to start with a therapeutic vaccine, Nexvax2, that has the potential  to protect coeliac patients from the adverse events caused by gluten exposure. Multicentre trials, including centres in Australia, are planned to start in mid 2018 to investigate whether regular use of the vaccine can desentisise patients with coeliac disease to ...

Already a member?

Login to keep reading.


OR
© 2021 the limbic